Adopting 3-Year Screening Intervals for Sight-Threatening Retinal Vascular Lesions in Type 2 Diabetic Subjects Without Retinopathy
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To report the incidence of sight-threatening vascular lesions in type 2 diabetic subjects without retinopathy after adopting a 3-year interval screening program. RESEARCH DESIGN AND METHODS: In all, 1,691 type 2 diabetic subjects with no detectable retinopathy in two 50° red-free fundus photographs were scheduled for follow-up with photography 3 years later. Age at diabetes diagnosis was 60 ± 12 years, and known duration of diabetes was 6 ± 6 years. Treatment consisted of diet only (26%), oral agents (54%), and oral agents and/or insulin (20%). Glycated hemoglobin A1c was 6.4 ± 1.5%. RESULTS: Of the 1,322 subjects available for follow-up, 73% were still without retinopathy after 3 years, and 28% had developed mild or moderate retinopathy, but none developed severe nonproliferative or proliferative retinopathy. Macular edema requiring laser coagulation occurred in only one eye. CONCLUSIONS: Three-year retinal screening intervals can be recommended in subjects with mild type 2 diabetes and no retinopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Artificial intelligence approaches to screening for diabetic retinopathy have progressed to the point of utility and cost-effectiveness.508–513”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [513]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wilkinson, C. P., Ferris, F. L., Klein, R. E., Lee, P. P., Agardh, C. D., Davis, M., Dills, D., Kampik, A., Pararajasegaram, R., & Verdaguer, J. T. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00475-5 · Cited by 3,743
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Screening and prevention of diabetic blindness
Stefánsson, E., Bek, T., Porta, M., Larsen, N., Kristinsson, J. K., & Agardh, E. (2000) · Acta Ophthalmologica Scandinavica · doi:10.1034/j.1600-0420.2000.078004374.x · Cited by 292 · cited 1×
“In Sweden, biennial screening examinations have long been standard for subjects without retinopathy (1).”
BackgroundSelf-citationYounis, N., Broadbent, D. M., Vora, J. P., & Harding, S. P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12267-2 · Cited by 289
Diabetic retinopathy screening: a systematic review of the economic evidence
Jones, S., & Edwards, R. T. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02870.x · Cited by 265 · cited 1×
“CONCLUSIONS—Screening for diabetic retinopathy is highly important for the individual in years of saved vision and for society with respect to costs associated with blindness and visual impairment (4).”
BackgroundKollias, A. N., & Ulbig, M. W. (2010) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2010.0075 · Cited by 253
Scanlon, P. H. (2008) · Journal of Medical Screening · doi:10.1258/jms.2008.008015 · Cited by 132
Alberti (1998) · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s · cited 1×
“The World Health Organization has lowered the limits for what are considered to be normal reference ranges for blood and plasma glucose levels (9), which has led to the earlier diagnosis of diabetes and has probably also lowered the risk of sightthreatening retinopathy.”
Background
Research works printed but not linked: 1
- Diabetic Retinopathy Screening Implementation Group, 2003, Diabetic retinopathy screening services in Scotland: recommendations for implementations, 69
Cited by
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
“Exams every 2 years may be cost-effective after one or more normal eye exams, and in a population with well-controlled type 2 diabetes there was essentially no risk of development of significant retinopathy with a 3-year interval after a normal examination (452).”
BackgroundStandards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
“Less-frequent exams (every 2–3 years) may be cost-effective after one or more normal eye exams, and in a population with well-controlled type 2 diabetes therewas essentially no risk of development of significant retinopathy with a 3-year interval after a normal examination (331).”
BackgroundKirkman, M. S., Briscoe, V. J., Clark, N., Florez, H., Haas, L. B., Halter, J. B., Huang, E. S., Korytkowski, M. T., Munshi, M. N., Odegard, P. S., et al. (2012) · Diabetes Care · doi:10.2337/dc12-1801 · Cited by 1,274
“For example, there is evidence, including in the older adult population, that dilated eye examinations that are initially normal can safely be repeated every 2–3 years instead of yearly (55).”
BackgroundDiabetic Retinopathy: A Position Statement by the American Diabetes Association
Solomon, S. D., Chew, E., Duh, E. J., Sobrin, L., Sun, J. K., VanderBeek, B. L., Wykoff, C. C., & Gardner, T. W. (2017) · Diabetes Care · doi:10.2337/dc16-2641 · Cited by 940
“Exams every 2 years may be cost-effective after one or more normal eye exams and, in a population with well-controlled type 2 diabetes, there was essentially no risk of development of significant retinopathy with a 3-year interval after a normal examination (26).”
BackgroundStandards of medical care for type 2 diabetes in China 2019
Jia, W., Weng, J., Zhu, D., Ji, L., Lu, J., Zhou, Z., Zou, D., Guo, L., Ji, Q., Chen, L., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3158 · Cited by 700
“In the absence of comprehensive eye screening by ophthalmologists, the nonmydriatic retinal photography of at least two posterior pole photographs at 45 ocular angles is a feasible screening method for diabetic retinopathy.(114) Patients with moderate or severe nonproliferative retinopathy identified during screening…”
MethodScreening for diabetic retinopathy: new perspectives and challenges
Vujosevic, S., Aldington, S. J., Silva, P., Hernández, C., Scanlon, P., Peto, T., & Simó, R. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30411-5 · Cited by 671
“[17-20] + (Diabetic Medicine (2019:36;1199-1208).”
Diabetes in Older Adults: A Consensus Report
Sue Kirkman, M., Briscoe, V. J., Clark, N., Florez, H., Haas, L. B., Halter, J. B., Huang, E. S., Korytkowski, M. T., Munshi, M. N., Odegard, P. S., et al. (2012) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12035 · Cited by 548
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s011 · Cited by 460
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s011 · Cited by 398
“terval after a normal examination (88).”
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s011 · Cited by 395
Thomas, R. L., Halim, S., Gurudas, S., Sivaprasad, S., & Owens, D. R. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107840 · Cited by 379
American Geriatrics Society Expert Panel on the Care of Older Adults with Diabetes Mellitus (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12514 · Cited by 326
10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s010 · Cited by 302
“ams every 1–2 yearsmay be cost-effective after one or more normal eye exams, and in a population with well-controlled type 2 diabetes, there was essentially no risk of development of significant retinopathy with a 3-year interval after a normal examination (81).”
Background12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gibbons, C. H., Giurini, J. M., Hilliard, M. E., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s012 · Cited by 207
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., Callaghan, B. C., ChallaSivaKanaka, S., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s012 · Cited by 214
10. Microvascular Complications and Foot Care
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s013 · Cited by 181
12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s012 · Cited by 177
“…well-controlled type 2 diabetes, there was little risk of development of signi fi cant retinopathy with a 3-year interval after a normal examination (15), and less frequent intervals have been found in simulated modeling to be potentially effective in screening for diabetic retinopathy in patients…”
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Callaghan, B. C., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s012 · Cited by 176
9. Microvascular Complications and Foot Care
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s012 · Cited by 172
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gibbons, C. H., Giurini, J. M., Hilliard, M. E., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s012 · Cited by 169
Voigt, M., Schmidt, S., Lehmann, T., Köhler, B., Kloos, C., Voigt, U., Meller, D., Wolf, G., Müller, U. A., & Muller, N. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-120570 · Cited by 160
Thomas, R. L., Dunstan, F., Luzio, S. D., Roy Chowdury, S., Hale, S. L., North, R. V., Gibbins, R. L., & Owens, D. R. (2012) · BMJ · doi:10.1136/bmj.e874 · Cited by 142
9. Microvascular Complications and Foot Care
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc15-s012 · Cited by 137
Extending the diabetic retinopathy screening interval beyond 1 year: systematic review
Taylor-Phillips, S., Mistry, H., Leslie, R., Todkill, D., Tsertsvadze, A., Connock, M., & Clarke, A. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305938 · Cited by 83
Evidence‐based Danish guidelines for screening of diabetic retinopathy
Grauslund, J., Andersen, N., Andresen, J., Flesner, P., Haamann, P., Heegaard, S., Larsen, M., Laugesen, C. S., Schielke, K. C., Skov, J., et al. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13936 · Cited by 82
on behalf of the Scottish Diabetes Research Network (SDRN) Epidemiology Group and the Scottish Diabetic Retinopathy Collaborative, Looker, H. C., Nyangoma, S. O., Cromie, D. T., Olson, J. A., Leese, G. P., Philip, S., Black, M. W., Doig, J., Lee, N., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-2928-7 · Cited by 80
“Iceland [8] and Sweden [9] have both reported on their positive experiences of switching individuals without evidence of retinopathy to longer screening intervals.”
BackgroundScreening intervals for diabetic retinopathy and incidence of visual loss: a systematic review
Echouffo-Tcheugui, J. B., Ali, M. K., Roglić, G., Hayward, R. A., & Narayan, K. M. V. (2013) · Diabetic Medicine · doi:10.1111/dme.12274 · Cited by 77
Screening Intervals for Diabetic Retinopathy and Implications for Care
Scanlon, P. H. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0928-6 · Cited by 59
The Diabetic Retinopathy Screening Workflow: Potential for Smartphone Imaging
Bolster, N. M., Giardini, M., & Bastawrous, A. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815617969 · Cited by 53
Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up
Romero-Aroca, P., de la Riva-Fernandez, S., Valls-Mateu, A., Sagarra-Alamo, R., Moreno-Ribas, A., Soler, N., & Puig, D. (2016) · BMC Ophthalmology · doi:10.1186/s12886-016-0318-x · Cited by 46
the ISDR Study Group, Broadbent, D., Wang, A., Cheyne, C. P., James, M., Lathe, J., STRATTON, I. M., Roberts, J., Moitt, T., Vora, J. P., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05313-2 · Cited by 52
Leese, G. P., Stratton, I. M., Land, M., Bachmann, M. O., Jones, C., Scanlon, P., Looker, H. C., & Ferguson, B. (2015) · Diabetes Care · doi:10.2337/dc14-1778 · Cited by 50
“,2% at 2 years (6,7), and lower for patients with newly diagnosed disease (8) and other defined groups (9).”
BackgroundForster, A. S., Forbes, A., Dodhia, H., Connor, C., Chemin, A. D., Sivaprasad, S., Mann, S. S., & Gulliford, M. C. (2013) · Diabetologia · doi:10.1007/s00125-013-2975-0 · Cited by 49
“Another study of 1,322 patients with type 2 diabetes did not observe any patients developing severe non-proliferative or proliferative retinopathy by 3 year follow-up if they had no retinopathy at baseline [24].”
BackgroundStrutton, R., Du Chemin, A., Stratton, I. M., & Forster, A. S. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010952 · Cited by 38
A decade-long telemedicine screening program for diabetic retinopathy in the north-east of Italy
Vujosevic, S., Pucci, P., Casciano, M., Daniele, A., Bini, S., Berton, M., Cavarzeran, F., Avogaro, A., Lapolla, A., & Midena, E. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.04.010 · Cited by 46
Validation of a model to estimate personalised screening frequency to monitor diabetic retinopathy
van der Heijden, A. A. W. A., Walraven, I., Riet, E. V. ‘., Aspelund, T., Lund, S. H., Elders, P. J. M., Polak, B. C. P., Moll, A. C., KEUNEN, J. E. E., Dekker, J. M., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3246-4 · Cited by 44
“Other studies have already shown that annual screening intervals can be safely prolonged for individuals at low risk of developing STR [2, 3, 10–16].”
BackgroundMethodScanlon, P. H., STRATTON, I. M., Histed, M. H., Chave, S., & Aldington, S. J. (2013) · Acta Ophthalmologica · doi:10.1111/aos.12074 · Cited by 44
“This risk may be based on a previous screening result (Agardh & Tababat-Khani 2011; Chalk et al. 2012; Olafsdottir & Stefansson 2007; Younis et al. 2003a,b) or on the basis of previously defined individual risk factors (Mehlsen et al. 2011, 2012).”
Backgroundfor the Individualised Screening for Diabetic Retinopathy (ISDR) Study Group, Eleuteri, A., Fisher, A. C., Broadbent, D. M., García-Fiñana, M., Cheyne, C. P., Wang, A., Stratton, I. M., Gabbay, M., Seddon, D., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4386-0 · Cited by 39
“Screening at 3-yearly intervals has been introduced in Sweden, based on data from one programme [10], and is supported as being cost-effective in a recent UK modelling study [11].”
BackgroundQuantification of risk factors for diabetic retinopathy progression
Tarasewicz, D., Conell, C. A., Gilliam, L. K., & Melles, R. B. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-02007-6 · Cited by 43
Bek, T. (2020) · Diabetologia · doi:10.1007/s00125-020-05234-0 · Cited by 42
Groeneveld, Y., Tavenier, D., Blom, J. W., & Polak, B. C. P. (2019) · Diabetic Medicine · doi:10.1111/dme.13908 · Cited by 39
Diabetic Retinopathy in Italy: Epidemiology Data and Telemedicine Screening Programs
Vujosevic, S., & Midena, E. (2016) · Journal of Diabetes Research · doi:10.1155/2016/3627465 · Cited by 35
“[47] E.”
ResultDiabetic retinopathy screening and treatment through the Brazilian National Health Insurance
Fernandes, A. G., Ferraz, A. N., Brant, R., & Malerbi, F. K. (2022) · Scientific Reports · doi:10.1038/s41598-022-18054-6 · Cited by 33
Trends of barriers to eye care among adults with diagnosed diabetes in Germany, 1997–2012
Baumeister, S., Schomerus, G., Andersen, R., Tost, F., Markus, M. R. P., Völzke, H., & Jürgens, C. (2015) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.07.003 · Cited by 32
Update on the American Diabetes Association Standards of Medical Care
Zitkus, B. S. (2014) · The Nurse Practitioner · doi:10.1097/01.npr.0000451880.48790.50 · Cited by 30
First Incidence and Progression Study for Diabetic Retinopathy in Portugal, the RETINODIAB Study
Dutra-Medeiros, M., Mesquita, E. M., Gardete-Correia, L., Moita, J. J., Genro, V., Papoila, A. L., Turkman, M. A. A., & Raposo, J. F. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.08.004 · Cited by 30
Soto‐Pedre, E., Piniés, J. A., & Hernáez-Ortega, M. C. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.12.020 · Cited by 28
Relationship Between Estimated Glucose Disposal Rate and Type 2 Diabetic Retinopathy
Meng, C., Xing, Y., Huo, L., & Ma, H. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s395818 · Cited by 27
“It is a practical way to screen for DR to take at least two 45° fundus color images in each eye, one with the optic disc centered and the other with the macula centered, by trained professionals employing non-mydriatic fundus cameras.(26) For patients with moderate or more than moderate nonproliferative retinopathy fo…”
MethodBroadbent, D., Sampson, C., Wang, A., Howard, L., Williams, A. E., Howlin, S. U., Appelbe, D. E., Moitt, T., Cheyne, C. P., Mobayen‐Rahni, M., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025788 · Cited by 27
Chen, X., Xie, Q., Zhang, X., Lv, Q., Liu, X., & Rao, H. (2021) · Journal of Diabetes Research · doi:10.1155/2021/3825155 · Cited by 27
Screening and Treatment by the Primary Care Provider of Common Diabetes Complications
Gilbert, M. P. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.09.002 · Cited by 27
Clinical characteristics influence screening intervals for diabetic retinopathy
Porta, M., Maurino, M., Severini, S., Lamarmora, E., Trento, M., Sitia, E., Coppo, E., Raviolo, A., Carbonari, S., Montanaro, M., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-2989-7 · Cited by 26
“More recently, Agardh et al [9] recommended 3-year screening intervals based on their case series in which only 1 out of 1,322 patients with type 2 diabetes, without DR at baseline, had developed a condition (macular oedema) requiring laser treatment within that time frame.”
Preferences of people with diabetes for diabetic retinopathy screening: a discrete choice experiment
Yeo, S. T., Edwards, R. T., Fargher, E., Luzio, S. D., Thomas, R., & Owens, D. R. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03636.x · Cited by 25
Liang, Y., Zhang, X., Mei, W., Li, Y., Du, Z., Wang, Y., Huang, Y., Zeng, X., Lai, C., Wang, S., et al. (2024) · Journal of Global Health · doi:10.7189/jogh.14.04192 · Cited by 24
Kalavar, M., Al-khersan, H., Sridhar, J. S., Gorniak, R., Lakhani, P. C., Flanders, A. E., & Kuriyan, A. E. (2020) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000333 · Cited by 24
Ochs, A., McGurnaghan, S. J., Black, M. W., Leese, G., Philip, S., Sattar, N. A., Styles, C., Wild, S. H., McKeigue, P., & Colhoun, H. M. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002945 · Cited by 23
“It includes DR screening results from both T1D and T2D patients, compared to other studies that included only one diabetes type [10,11].”
ResultConlin, P. R., Asefzadeh, B., Pasquale, L. R., Selvin, G., Lamkin, R., & Cavallerano, A. A. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-306536 · Cited by 20
Tsujimoto, T., & Kajio, H. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.07.031 · Cited by 19
Nakayama, Y., Yamaguchi, S., Shinzato, Y., Okamoto, S., Millman, J. F., Yamashiro, K., Takemoto, N., Uema, T., Arakaki, K.-I., Higa, M., et al. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej20-0630 · Cited by 19
“Incidence of DR was assessed by worsening in stage (from stage 1 to stage 2 or stage 3), and progres‐ sion of DR was defined as a worsening in stage (from stage 2 to stage 3) [18, 19].”
MethodChamard, C., Daïen, V., Erginay, A., Gautier, J., Villain, M., Tadayoni, R., Carrière, I., & Massin, P. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316030 · Cited by 18
Thomas, R., Winfield, T. G., Prettyjohns, M., Dunstan, F., Cheung, W., Anderson, P. M., Peter, R., Luzio, S. D., & Owens, D. R. (2020) · The European Journal of Health Economics · doi:10.1007/s10198-020-01191-y · Cited by 18
Limwattanayingyong, J., Nganthavee, V., Seresirikachorn, K., Singalavanija, T., Soonthornworasiri, N., Ruamviboonsuk, V., Rao, C., Raman, R., Grzybowski, A. E., Schaekermann, M., et al. (2020) · Journal of Diabetes Research · doi:10.1155/2020/8839376 · Cited by 18
“Extending the screening interval from annual to once every 2-3 years was found to be cost-effective in several studies in Europe [13, 14].”
BackgroundSharif, A., JENDLE, J. H., & Hellgren, K. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00957-0 · Cited by 17
Noninvasive Retinal Markers in Diabetic Retinopathy: Advancing from Bench towards Bedside
Blindbæk, S. L., Torp, T. L., Lundberg, K., Soelberg, K. K., Vergmann, A. S., Poulsen, C. D., Frydkjær-Olsen, U., Broe, R., Rasmussen, M. L., Wied, J., et al. (2017) · Journal of Diabetes Research · doi:10.1155/2017/2562759 · Cited by 17
Chung, Y.-C., Xu, T., Tung, T., Chen, M., & Chen, P. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.771862 · Cited by 15
Loewenstein, A., Berger, A. R., Daly, A., Creuzot-Garcher, C. P., Gale, R. P., Ricci, F., Zarranz‐Ventura, J., & Guymer, R. H. (2023) · Eye · doi:10.1038/s41433-023-02540-w · Cited by 15
Complicaciones microvasculares de la diabetes
García-Ocaña, P., Cobos-Palacios, L., & Martínez, L. F. C. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.09.012 · Cited by 15
Complicaciones microvasculares de la diabetes
Pérez‐Pevida, B., Llavero, M., Gargallo, J., & Escalada, J. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.09.003 · Cited by 15
Early diagnostic of diabetic foot using thermal images
Cajacuri, L. A. V. (2013) · theses.fr (ABES) · doi:10.70675/a22bf653zda6fz4a91zbd90z2f11c7afabe4 · Cited by 15
Thomas, R., Distiller, L. A., Luzio, S. D., Melville, V. J., Chowdhury, S. R., Kramer, B. D., & Owens, D. R. (2015) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2015.1090159 · Cited by 14
Diabetic retinopathy—recommendations for screening and treatment
Pedrini, A., Nowosielski, Y., & Rehák, M. (2025) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-025-01088-6 · Cited by 11
Heimann, H., Broadbent, D., & Cheeseman, R. (2020) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1300-7779 · Cited by 11
“A recent study carried out in Malmö prospectively followed people with type 2 diabetes and no retinopathy and concluded that it appeared safe to adopt 3-year intervals, as suggested by the Liverpool group [34,35].”
BackgroundOwolabi, E. O., Goon, D. T., Ajayi, A. I., Adeniyi, O. V., & Chu, K. (2022) · South African Family Practice · doi:10.4102/safp.v64i1.5447 · Cited by 10
Diabetic retinopathy screening using a virtual reading center
Melles, R. B., Conell, C. A., Siegner, S. W., & Tarasewicz, D. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01392-9 · Cited by 10
A systematic review of diabetic retinopathy screening intervals
Drinkwater, J. J., Kalantary, A., & Turner, A. W. (2023) · Acta Ophthalmologica · doi:10.1111/aos.15788 · Cited by 9
Yeo, S. T., Edwards, R. T., Luzio, S. D., Charles, J. M., Thomas, R., Peters, J. M., & Owens, D. R. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03637.x · Cited by 9
Byrne, P., Thetford, C., Gabbay, M., Clarke, P. M., Doncaster, E., Harding, S. P., for the ISDR Study Group, Harding, S. P., Broadbent, D., Byrne, P., et al. (2020) · BMC Public Health · doi:10.1186/s12889-020-08974-1 · Cited by 9
Toward Optimal Screening for Diabetic Retinopathy: Balancing Precision and Pragmatism
Barkmeier, A. J. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.12.008 · Cited by 8
Junior, P. P. D. O., & de Castro, F. A. G. (2022) · Revista Brasileira de Medicina de Família e Comunidade · doi:10.5712/rbmfc17(44)3239 · Cited by 7
Should diabetes retinal screening intervals change?
Leese, G. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03752.x · Cited by 7
Hughes, D., Nair, S., & Harvey, J. N. (2016) · Journal of Medical Screening · doi:10.1177/0969141316672687 · Cited by 7
“Sweden, Iceland, and New Zealand have already taken the decision to screen such patients every two years.(7,17) The current evidence in support of this comes primarily from large screening programmes assessing numbers who progress to STR by photographic criteria.”
BackgroundWeltermann, B., Reinders, S., Bettin, M., Gesenhues, S., & Hermann, M. (2012) · Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen · doi:10.1016/j.zefq.2012.11.019 · Cited by 7
Harding, S. P., Alshukri, A., Appelbe, D., Broadbent, D., Burgess, P. I., Byrne, P., Cheyne, C. P., Eleuteri, A., Fisher, A., García‐Fiñana, M., et al. (2023) · Programme Grants for Applied Research · doi:10.3310/hrfa3155 · Cited by 6
A Decision-Support Software to Improve the Standard Care in Chinese Type 2 Diabetes
Luo, Y., Zhu, Y., Chen, J., Gao, X., Yang, W., Zou, X., Zhou, X., & Ji, L. (2019) · Journal of Diabetes Research · doi:10.1155/2019/5491743 · Cited by 6
Forecasting the diabetic retinopathy progression using generative adversarial networks
Qiao, H., Tang, F., Zhou, H., Cai, Y., Guo, K., Wang, J., Ma, T., Ju, L., Feng, W., Ma, Z., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01092-2 · Cited by 5
James, M., Goodchild, C., Bashir, S., & Mannix, M. (2015) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-015-1248-y · Cited by 5
Real-world outcomes of a clinical decision support system for diabetic retinopathy in Spain
Romero‐Aroca, P., Verges, R., Maaroof, N., Mateu, A. V., Latorre, A., Moreno, A., Sagarra-Alamo, R., Basora, J., Cristiano, J., & Baget‐Bernaldiz, M. (2022) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2022-000974 · Cited by 5
Quality of diabetes care in family medicine practices in eastern Bosnia and Herzegovina
Račić, M., Kusmuk, S., Mašić, S., Ristić, S., Ivković, N., Djukanović, L., & Božović, D. (2014) · Primary care diabetes · doi:10.1016/j.pcd.2014.05.006 · Cited by 5
“Examinations will be required more frequently if retinopathy is progressing [13,14].”
BackgroundAravindhan, A., Fenwick, E., Chan, A. W. D., Man, R. E. K., Tan, N. C., Wong, W. T., Soo, W. F., Lim, S. W., Wee, S. Y.-M., Sabanayagam, C., et al. (2024) · BMC Public Health · doi:10.1186/s12889-024-18287-2 · Cited by 4
“…screening visits could be safely extended beyond 12 months [17] with high adherence rates [18] and no undue delays in treatment for ref-erable DR in patients with diabetes without DR [19–21], Moreover, extending the screening intervals beyond one year has been found to be cost-effective [22–24].”
BackgroundThe Danish Ophthalmological Society guidelines for screening of diabetic retinopathy
Grauslund, J., Andersen, N., Andresen, J. L., Bek, T., Knudsen, S. T., & Subhi, Y. (2025) · AJO International · doi:10.1016/j.ajoint.2025.100141 · Cited by 4
Stratifying the NHS Diabetic Eye Screening Programme: into the unknown?
Sampson, C., James, M., Broadbent, D., & Harding, S. P. (2016) · Diabetic Medicine · doi:10.1111/dme.13192 · Cited by 4
Screening for sight-threatening diabetic retinopathy: An update
Scanlon, P. H., Dirani, M., & van Wijngaarden, P. (2014) · Egyptian Retina Journal · doi:10.4103/2347-5617.152479 · Cited by 4
Diabetes-Related Microvascular Complications: What Every Nurse Practitioner Needs to Know
Egan, E. A. (2017) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2016.08.030 · Cited by 3
Olivieri, C., Salato, M., Campanella, A., Marolo, P., Parisi, G., Neri, G., Toro, M. D., Scarmozzino, A., Broglio, F., Borrelli, E., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02354-6 · Cited by 3
“Several European studies have reported that extending the screening interval from annually to every 2 or 3 years in patients with diabetes who initially show no evidence of retinopathy can be cost-effective [30, 31].”
Resultados de un cribado de retinopatía diabética. Análisis de marcadores de riesgo
Ancochea, G., & Sánchez, M. D. (2015) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2015.09.011 · Cited by 3
Results of a diabetic retinopathy screening. Risk markers analysis
Ancochea, G., & Sánchez, M. D. (2016) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2015.12.001 · Cited by 3
Deep Learning Model to Predict the Risk of Developing Diabetic Retinopathy
Prathyusha, P., Mallareddy, A., & Suryanarayana, S. V. (2022) · CVR Journal of Science & Technology · Cited by 2
Sulak, M., Jevnikar, K., Drnovšek, F., Vrhovec, L., Urbančič, M., Potrč, M., Thaler, A., Čokl, N., Zaletel, J., & Petrovič, M. G. (2024) · European Journal of Ophthalmology · doi:10.1177/11206721241267029 · Cited by 2
“22,27 Consequently, the UK National Screening Committee recommended a change from a 1-year to 2-year re-screening interval for people at low risk of sight loss, de fi ned as no DR detected at two successive eye screening examinations.”
Metadata
- Authors
- Agardh, E., & Tababat-Khani, P.
- Affiliations
- Lund University (SE)
- Department of Clinical Sciences Malmö, Ophthalmology, Skåne University Hospital Malmö, Lund University, Malmö, Sweden.
- Corresponding author
- Agardh, Elisabet
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-05-20
- Volume
- 34
- Issue
- 6
- Pages
- 1318-1319
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3114331
- OpenAlex
- W2120206300
- Cited by
- 113
- References
- 8
- Citations by year
- 2025: 6 · 2024: 11 · 2023: 6 · 2022: 9 · 2021: 4 · 2020: 13 · 2019: 9 · 2018: 2 · 2017: 8 · 2016: 7 · 2015: 11 · 2014: 8 · 2013: 10 · 2012: 8
- FWCI
- 8.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Ögonfonden
- Stiftelsen för Synskadade i f.d. Malmöhus län
- Lunds Universitet
- Svenska Läkaresällskapet
- Skånes universitetssjukhus
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, diabetic retinopathy, retinal vascular lesions, macular edema, retinopathy progression, HbA1c
- MeSH terms
- Adult, Aged, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Humans, Macular Edema, Middle Aged, Prospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
